Trazodone withdrawal can be eliminated
with this program. Trazodone withdrawal has a solution. If
you are taking Trazodone as well as an anti-anxiety
medication (benzodiazepine), the anti-anxiety medication
must be discontinued first. If you are only discontinuing
the Trazodone the Trazodone must be reduced very slowly to
prevent withdrawal side effects from the anti-anxiety drug.
Trazodone slows the metabolism rate of anti-anxiety drugs
and when the Trazodone is removed from the system the
anti-anxiety medication will not take as long to metabolize
and this creates a withdrawal effect from the anti-anxiety
medication. See chapter 9 on the right side of each page for
anti-anxiety medication procedures.
Trazodone Withdrawal
Insomnia and anxiety during the daytime? What a
question right? Of course you have these two
symptoms.
To get to the point; two supplements have been
formulated to help with these two Trazodone side
effects. Neuro Day and Neuro Night.
Neuro Day
- Take 1 capsule twice a day 4 to 5 hours apart
Neuro Night
- Take 1 capsule 15 minutes before bedtime.
Click here
to purchase.
The web site you are on now, The Road Back, offers
information on how to get off Trazodone, prevent
Trazodone withdrawal side effects as well as
eliminating current Trazodone side effects.
Trazodone withdrawal just got easier with a new
breakthrough by our founder and author of How to Get
Off Psychoactive Drugs Safely, Jim Harper.
Withdrawal off of Trazodone does not have to be
difficult and handling current Trazodone side
effects can be resolved quickly.
Note:
If you are taking Trazodone as well as an
anti-anxiety medication (benzodiazepine), the
anti-anxiety medication must be discontinued first.
If you are only discontinuing the Trazodone the
Trazodone must be reduced very slowly to prevent
withdrawal side effects from the anti-anxiety drug.
Trazodone slows the metabolism rate of anti-anxiety
drugs and when the Trazodone is removed from the
system the anti-anxiety medication will not take as
long to metabolize and this creates a withdrawal
effect from the anti-anxiety medication. See chapter
9 on the right side of each page for anti-anxiety
medication procedures.
In Nov., 2016, our program made its next leap forward
and at this time; completely eliminating Trazodone
side effects is not only within our grasp, it is
here.
Anxiety in the daytime, insomnia at night, the
dreaded head symptoms common with Trazodone
withdrawal can now be a thing of the past.
There is quite a bit of information on our web site
and if the ill effects from Trazodone have you
unable to read very much text, we can make this very
quick and simple. Just do what is described
above.
For head symptoms, even the electric brain zaps,
taking the right type of omega 3 fish oil will
eliminate them quickly. Take (2) Omega 3 Supreme in
the morning and (2) more at noon.
If you have nausea, drink a couple cups of ginger
tea each day.
Trazodone
Brand name (Desyrel)
Pharmacology
Antidepressant
Trazodone is a psychoactive compound with sedative and anti-depressant
properties. Its mechanism of action in humans is not
clear.
Trazodone is well absorbed after oral administration with mean peak
plasma levels obtained within 0.5 to 2 hours after
ingestion. Absorption is somewhat delayed and enhanced by
food. The mean plasma elimination half-life is 4.4 hours
for the period from 3 to 10 hours after dosing, and 7 to 8
hours for the period from 10 to 34 hours. The drug is
extensively metabolized with 3 or 4 major metabolites having
been identified in man. Approximately 60 to 70% of
C14-labelled trazodone was found to be excreted in the urine
within 2 days and 9 to 29% in feces over 60 to 100 hours.
Trazodone is 89 to 95% protein bound in vitro at
concentrations attained with therapeutic doses.
Indications
For the
symptomatic relief of depressive illness.
Contraindications
Known
hypersensitivity to trazodone.
Warnings
Trazodone
has been associated with the occurrence of priapism. In
approximately 33% of the cases reported, surgical
intervention was required and, in a portion of these cases,
permanent impairment of erectile function or impotence
resulted. Male patients with prolonged or inappropriate
erections should immediately discontinue the drug and
consult their physician. If the condition persists for more
than 24 hours, it would be advisable for the treating
physician to consult a urologist or appropriate specialist
in order to decide on a management approach. Recent clinical
studies in patients with pre-existing cardiac disease
indicate that trazodone may be arrhythmogenic in some
patients in that population. Arrhythmias identified include
isolated PVC's, ventricular couplets, and in 2 patients
short episodes (3 to 4 beats) of ventricular tachycardia.
There have also been several post-marketing reports of
arrhythmias in trazodone-treated patients who have
pre-existing cardiac disease and in some patients who did
not have pre-existing cardiac disease. Until the results of
prospective studies are available, patients with
pre-existing cardiac disease should be closely monitored,
particularly for cardiac arrhythmias. Trazodone is not
recommended for use during the initial recovery phase of
myocardial infarction.
Precautions
The
possibility of suicide in depressed patients remains during
treatment and until significant remission occurs. Therefore,
the number of tablets prescribed at any one time should take
into account this possibility, and patients with suicide
ideation should never have access to large quantities of
trazodone.
Episodes of grand mal seizures have been reported in a small number of
patients. The majority of these patients were already
receiving anticonvulsant therapy for a previously diagnosed
seizure disorder.
Occupational Hazards:
Since trazodone may impair the mental and/or physical abilities required
for performance of potentially hazardous tasks, such as
operating an automobile or machinery, the patient should be
cautioned not to engage in such activities while impaired.
Drug Interactions:
Trazodone may enhance the response to alcohol and the effects of
barbiturates and other CNS depressants and patients should
be cautioned accordingly.
Increased serum digoxin and phenytoin levels have been reported to occur
in patients receiving trazodone concurrently with either of
those 2 drugs. Little is known about the interaction between
trazodone and general anesthetics; therefore, prior to
elective surgery, trazodone should be discontinued for as
long as clinically feasible.
Because it is not known whether an interaction will occur between
trazodone and MAO inhibitors, administration of trazodone
should be initiated very cautiously with gradual increase in
dosage as required, if an MAO inhibitor is given
concomitantly or has been discontinued shortly before
medication with trazodone is instituted.
Trazodone may cause hypotension including orthostatic hypotension and
syncope; caution is required if it is given to patients
receiving antihypertensive drugs and an adjustment in the
dose of the antihypertensive medication may be required.
Because of the absence of experience, concurrent administration of
electro-shock therapy should be avoided.
Pregnancy and Lactation:
Since the safety and use of trazodone in pregnant women has not been
established, it should not be used in women of childbearing
potential unless in the opinion of the physician the
expected benefits justify the potential risk to the fetus.
Since trazodone and/or its metabolites have been detected in
the milk of lactating animals, it should not be administered
to nursing mothers unless the potential benefits justify the
possible risks to the child.
Children:
The safety and effectiveness of trazodone in children below the age of 18
have not been established.
Laboratory tests:
It is recommended that white blood cell and differential counts should be
performed in patients who develop sore throat, fever, or
other signs of infection or blood dyscrasia and trazodone
should be discontinued if the white blood cell or absolute
neutrophil count falls below normal.
Hyperprolactinemia and breast tumors:
There is sufficient experimental evidence to conclude that chronic
administration of those psychotropic drugs, such as
trazodone, which increase prolactin secretion has the
potential to induce mammary neoplasms in rodents under
appropriate conditions. Tissue culture experiments indicate
that approximately 33% of human breast cancers are prolactin
dependent in vitro, a factor of potential importance if the
prescription of these drugs is contemplated in a patient
with a previously detected breast cancer. Although
disturbances such as galactorrhea, amenorrhea, gynecomastia
and impotence have been reported, the clinical significance
of elevated serum prolactin levels or increased secretion
and turnover are unknown for most patients. Neither clinical
studies nor epidemiological studies conducted to date,
however, have shown an association between administration of
these drugs and mammary tumorigenesis: Available evidence is
considered too limited to be conclusive at this time.
Adverse Effects
The most
common adverse reactions encountered are drowsiness,
nausea/vomiting, headache and dry mouth. Adverse reactions
reported include the following:
Behavioral:
Drowsiness, fatigue, lethargy, retardation, lightheadedness, dizziness,
difficulty in concentration, confusion, impaired memory,
disorientation, excitement, agitation, anxiety, tension,
nervousness, restlessness, insomnia, nightmares, anger,
hostility and, rarely, hypomania, visual distortions,
hallucinations, delusions and paranoia.
Neurologic:
Tremor, headache, ataxia, akathisia, muscle stiffness, slurred speech,
retarded speech, vertigo, tinnitus, tingling of extremities,
paresthesia, weakness, grand mal seizures (see Precautions),
and, rarely impaired speech, muscle twitching, numbness,
dystonia and involuntary movements.
Autonomic:
Dry mouth, blurred vision, diplopia, miosis, nasal congestion,
constipation, sweating, urinary retention, increased urinary
frequency and incontinence.
Cardiovascular:
Orthostatic hypotension, hypertension, tachycardia, palpitations,
shortness of breath, apnea, syncope, arrhythmias, prolonged
P-R interval, atrial fibrillation, bradycardia, ventricular
ectopic activity (including ventricular tachycardia),
myocardial infarction and cardiac arrest.
Gastrointestinal:
Nausea, vomiting, diarrhea, gastrointestinal discomfort, anorexia,
increased appetite.
Endocrine:
Priapism, decrease and, more rarely, increase in libido, weight gain and
loss, and rarely, menstrual irregularities, retrograde
ejaculation and inhibition of ejaculation.
Allergic or toxic:
Skin rash, itching, edema, and, rarely, hemolytic anemia,
methemoglobinemia, liver enzyme alterations, obstructive
jaundice, leukocytoblastic vasculitis, purpuric
maculopapular eruptions, photosensitivity and fever.
Miscellaneous:
Aching joints and muscles, peculiar taste, hypersalivation, chest pain,
hematuria, red, tired and itchy eyes.
Overdose
Symptoms:
Overdosage of trazodone may cause an increase in incidence or severity of
any of the reported adverse reactions, e.g. hypotension and
excessive sedation. In one known suicide attempt, the
patient presented with symptoms of drowsiness and weakness 3
hours after ingesting 7.5 g (12.5 times the maximum daily
dose) of trazodone. Recovery was uneventful. Death by
deliberate or accidental overdosage has not been reported.
Treatment:
There is no specific antidote for trazodone. Management of overdosage
should, therefore, be symptomatic and supportive. Any
patient suspected of having taken an overdosage should be
admitted to hospital as soon as possible and the stomach
emptied by gastric lavage. Forced diuresis may be useful in
facilitating elimination of the drug.
Dosage
Dosage
should be initiated at a low level and increased gradually
noting carefully the clinical response and any evidence of
intolerance. It should be kept in mind that there may be a
lag in the therapeutic response. Increasing the dosage
rapidly does not normally shorten this latent period and may
increase the incidence of side effects.
Usual adult dosage:
The recommended initial dose is 150 to 200 mg daily, in 2 or 3 divided
doses. Trazodone should be taken shortly after a meal or
light snack in order to reduce the incidence of adverse
reactions. The initial dose may be increased according to
tolerance and response by increments of 50 mg, usually up to
300 mg daily in divided doses. In some patients, doses up to
400 mg daily and rarely up to 600 mg daily in hospitalized
patients, may be required. Occurrence of drowsiness may
require the administration of a major portion of the daily
dose at bedtime or a reduction of dosage. Once an adequate
response has been achieved, the dosage may be gradually
reduced, with adjustment depending on therapeutic response.
During prolonged maintenance therapy the dosage should be
kept at the lowest effective level.
Use in the elderly:
If used in the elderly, doses not exceeding one-half the recommended
adult dosage should be used, with adjustments made depending
on tolerance and response.
Because safety and effectiveness in children have not been established
trazodone is not recommended in the pediatric age group.
Supplied
Desyrel:
Each orange, round, film-sealed, scored tablet contains:
Trazodone hydrochloride 50 mg. Bottles of 100 and 250.
Each white, round, film-sealed, scored tablet contains: Trazodone
hydrochloride 100 mg. Bottles of 100.
Desyrel Dividose:
Each orange rectangular-shaped, trisected and bisected
tablet contains: Trazodone hydrochloride 150 mg. Each tablet
can be broken accurately to provide any of the following
dosages: 50 mg (1/3 tablet), 75 mg (1/2 of a tablet), 100 mg
(2/3 of a tablet), 150 mg (entire tablet). To break a
Dividose tablet accurately and easily, hold the tablet
between your thumbs and index fingers, close to the
appropriate score (groove). Then with the tablet score
facing you, apply pressure and snap the tablet segments
apart. Bottles of 100.
|